TLDR Jim Cramer warned investors against buying “parabolic” tech and AI stocks, saying the trades often reverse fast He said better opportunities exist in overlookedTLDR Jim Cramer warned investors against buying “parabolic” tech and AI stocks, saying the trades often reverse fast He said better opportunities exist in overlooked

Jim Cramer Warns Against Chasing Parabolic Stocks – Here’s Where He’s Putting His Money

2026/04/21 21:58
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]

TLDR

  • Jim Cramer warned investors against buying “parabolic” tech and AI stocks, saying the trades often reverse fast
  • He said better opportunities exist in overlooked, out-of-favor stocks
  • Cramer’s Charitable Trust bought Johnson & Johnson shares while the stock was falling
  • He called J&J his favorite drug stock, above Eli Lilly, citing its pipeline and business transformation
  • Cramer stressed the need for portfolio diversification between hot and cold names

Jim Cramer, host of CNBC’s Mad Money, told investors on Monday to stop chasing the market’s biggest winners and start looking at what everyone else is ignoring.

Cramer said stocks making “parabolic” moves, especially in tech and AI, are dangerous to buy. He said when he buys into those kinds of moves, he tends to lose money.

Instead of chasing stocks like Intel or Advanced Micro Devices, Cramer said he is doing the opposite. He is buying quality companies that have sold off and fallen out of favor with the market.

His CNBC Investing Club Charitable Trust recently bought shares of Johnson & Johnson while the stock was still dropping. The health-care sector is currently the worst-performing sector in the S&P 500 this year.

Why Cramer Is Backing Johnson & Johnson

Cramer said Johnson & Johnson is now his favorite drug stock, a position previously held by Eli Lilly. He cited the company’s drug pipeline and its ongoing business transformation as reasons for his confidence.


JNJ Stock Card
Johnson & Johnson, JNJ

Johnson & Johnson has been shedding slower-growing divisions and focusing more on pharmaceutical research. The company has multiple drugs in late-stage development and several recent approvals.

Cramer said recent weakness in the stock has been driven mostly by noise, particularly concerns around talc lawsuits. He argued those concerns have overshadowed real progress inside the company.

The Case for Diversification

Cramer’s broader point was about how investors build their portfolios. He said owning only the hottest names is risky because sentiment can shift quickly.

If one area of the market falls out of favor, owning some undervalued names means you still have something working. Cramer said this was a lesson he learned at Goldman Sachs.

Health care stocks have been hit hard in 2025. Johnson & Johnson shares are down over the past year, with the stock falling around 1.57% in recent sessions alongside continued sector pressure.

The post Jim Cramer Warns Against Chasing Parabolic Stocks – Here’s Where He’s Putting His Money appeared first on CoinCentral.

Market Opportunity
Intuition Logo
Intuition Price(TRUST)
$0.06596
$0.06596$0.06596
-0.67%
USD
Intuition (TRUST) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

USD1 Genesis: 0 Fees + 12% APR

USD1 Genesis: 0 Fees + 12% APRUSD1 Genesis: 0 Fees + 12% APR

New users: stake for up to 600% APR. Limited time!